Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Intra-Articular Injection of RAB001 for Injection in Participants With Knee Osteoarthritis

NCT07652372 is registered in ClinicalTrials.gov with ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. as lead sponsor.

NCT NCT07652372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07652372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Intra-Articular Injection of RAB001 for Injection in Participants With Knee Osteoarthritis
Lead sponsor
ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
April 16, 2026
Completion date
September 30, 2027
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

knee osteoarthritis